Results 301 to 310 of about 133,417 (336)
Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study. [PDF]
Cancer Immunol ImmunotherLai M +7 more
europepmc +1 more source
Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer [PDF]
memo - Magazine of European Medical Oncology, 2020 In locally advanced rectal cancer, neoadjuvant chemoradiotherapy provides a significant benefit to local cancer control in addition to total mesorectal excision. However, in 10–40% of all patients, a complete clinical remission can be detected after completion of chemoradiotherapy.
Fabian Lunger, Georgios Peros
openaire +1 more source
Chemoradiotherapy for gastrointestinal cancers [PDF]
Current Oncology Reports, 2005 New combinations of chemotherapy with radiotherapy for gastrointestinal cancers are showing evidence that improved outcomes may result from toxicity profiles associated with "targeted" systemic radiosensitizing agents. These new agents are also clinically attractive owing to such factors as oral bioavailability and patient dosing schedules, making them
Joshua D. Lawson +3 more
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Chemoradiotherapy for Rectal Cancer
New England Journal of Medicine, 2005Non ...
Ferretti G, Bria E, Mandala' M
openaire +4 more sources
Timing and sequencing of chemoradiotherapy [PDF]
, 1995 There are three main objectives in the treatment of cancer: (1) curing disease, (2) keeping the morbidity of treatment to a minimum, and (3) preserving function and cosmesis. It may be difficult to achieve all three of these objectives in all cases. However, cure may be the most important single goal.
Everett E. Vokes +2 more
openaire +2 more sources
Chemoradiotherapy in gallbladder cancer
Journal of Surgical Oncology, 2006AbstractGallbladder cancer (GC) is considered a rare disease associated with a poor prognosis. Unfortunately, the low number of cases makes the performance of trials addressing the role of adjuvant, neoadjuvant, and/or palliative therapy difficult. For a long time, the majority of trials were 5‐fluorouracil (5 FU)‐based, and results were uniformly poor.
Andres Cordova +10 more
openaire +3 more sources
Chemoradiotherapy in Gastrointestinal Malignancies
Clinical Oncology, 2009Over the past 30 years, significant advances have been made in the integration of radiation therapy and chemotherapy in the treatment of patients with localised gastrointestinal malignancies. The therapeutic goal of chemoradiotherapy is to enhance local control resulting in improved survival and outcome of these patients. To define the optimal sequence,
Christopher G. Willett, Brian G. Czito
openaire +3 more sources
Rationale for chemoradiotherapy
International Journal of Clinical Oncology, 2004The rationale for combining chemotherapy (CT) and radiotherapy (RT) is based mainly on two ideas, one being spatial cooperation and the other the enhancement of radiation effects. Spatial cooperation is effective if CT is sufficiently active to eradicate subclinical metastases and if the primary local tumor is effectively treated by RT. In this regard,
openaire +3 more sources
Pancreatic cancer chemoradiotherapy
Best Practice & Research Clinical Gastroenterology, 2016Pancreatic cancer is the most lethal gastrointestinal tumour. Chemotherapy is the mainstay of therapy in the majority of the patients whereas resection is the only chance of cure but only possible in 15-20% of all patients. The integration of radiotherapy into multimodal treatment concepts is heavily investigated.
Thomas Brunner +2 more
openaire +4 more sources